PSORIASIS

All Classes (Updated 08/28/2024)

DISEASE/CONDITION	EVALUATION DATA	DISPOSITION
A. Mild to moderate disease confined to the skin AND Treated with topical medication only	If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties:	ISSUE Annotate this information in Block 60.
B. Mild to moderate disease	See the CACI - Psoriasis Worksheet	
AND Treated with oral or injectable medication If psoriatic arthritis present, see CACI – Arthritis Worksheet	This requires a current, detailed Clinical Progress Note from the treating physician. (Labs required if taking methotrexate.) If the pilot meets all CACI worksheet criteria and is otherwise qualified:	ISSUE Annotate (elements or findings) in Block 60. Annotate the correct CACI statement in Block 60 and keep the required supporting information on file.
C. All others including:	Submit the following for FAA review:	
 Erythrodermic psoriasis Pustular psoriasis Severe psoriasis 	A current, detailed Clinical Progress Note generated from a clinic visit with the treating Dermatologist or Rheumatologist no more than 90 days prior to the AME exam. It must include: • A detailed summary of the history of the condition; • Current medications, dosage, and side effects (if any); • Physical exam findings; • Results of any testing performed; • Diagnosis; • Assessment and plan; • Prognosis; and • Follow-up. The Clinical Progress Note must specifically	DEFER Submit the information to the FAA for a possible Special Issuance Annotate (elements or findings) in Block 60.
	 include: If any co-morbid conditions are present Documentation of counseling on guideline-directed screening for co-morbid conditions See <u>Pilot Information – Clinical Progress Note</u>. 	